<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57032">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01918033</url>
  </required_header>
  <id_info>
    <org_study_id>4117-200</org_study_id>
    <secondary_id>MK-4117-200</secondary_id>
    <secondary_id>132244</secondary_id>
    <nct_id>NCT01918033</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)</brief_title>
  <official_title>A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the efficacy and safety of desloratadine in Japanese
      participants with perennial allergic rhinitis. The primary hypothesis is that desloratadine
      is superior to placebo after 2 weeks of treatment with regard to change from baseline in
      total nasal symptom score among Japanese participants with perennial allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Total Nasal Symptom Score Assessed by the Investigator at Week 2</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to Week 4</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Discontinuing Study Treatment Due to an AE</measure>
    <time_frame>Up to Week 2</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Nasal Symptom Score Assessed by the Investigator</measure>
    <time_frame>Baseline, Day 3, Week 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nasal Symptom Sub-Score Assessed by the Investigator</measure>
    <time_frame>Baseline, Day 3, Week 1, Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nasal Finding Score Assessed by the Investigator</measure>
    <time_frame>Baseline, Day 3, Week 1, Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eye Symptom Score Assessed by the Investigator</measure>
    <time_frame>Baseline, Day 3, Week 1, Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Moderate-to-Remarkable Improvement in 5 Ratings of Global Improvement Rate Assessed by the Investigator</measure>
    <time_frame>Day 3, Week 1, Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Score on Interference With Daily Activities Assessed by the Investigator</measure>
    <time_frame>Baseline, Day 3, Week 1, Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nasal Symptom Score Reported in Participant Diaries</measure>
    <time_frame>Baseline, Day 3, Week 1, Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eye Symptom Score Reported in Participant Diaries</measure>
    <time_frame>Baseline, Day 3, Week 1, Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">608</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Desloratadine 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desloratadine 10 mg administered orally once daily for up to 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desloratadine 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desloratadine 5 mg administered orally once daily for up to 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo to desloratadine administered orally once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desloratadine 10 mg</intervention_name>
    <description>Desloratadine 10 mg once daily for up to 2 weeks.</description>
    <arm_group_label>Desloratadine 10 mg</arm_group_label>
    <other_name>MK-4117</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desloratadine 5 mg</intervention_name>
    <description>Desloratadine 5 mg once daily for up to 2 weeks.</description>
    <arm_group_label>Desloratadine 5 mg</arm_group_label>
    <other_name>MK-4117</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to desloratadine once daily for up to 2 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with  perennial allergic rhinitis;

          -  Outpatient.

        Exclusion Criteria:

          -  Participants with lower respiratory tract infection and participants who have a
             nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute
             pharyngolaryngitis, or acute tonsillitis, etc.)

          -  History of hypersensitivity to antihistamines or study drug;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 6, 2014</lastchanged_date>
  <firstreceived_date>August 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinitis</keyword>
  <keyword>Allergic Rhinitis</keyword>
  <keyword>Nose Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Cholinergic Antagonists</keyword>
  <keyword>Cholinergic Agents</keyword>
  <keyword>Neurotransmitter Agents</keyword>
  <keyword>Histamine H1 Antagonists, Non-Sedating</keyword>
  <keyword>Histamine H1 Antagonists</keyword>
  <keyword>Histamine Antagonists</keyword>
  <keyword>Histamine Agents</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
    <mesh_term>Cholinergic Antagonists</mesh_term>
    <mesh_term>Neurotransmitter Agents</mesh_term>
    <mesh_term>Histamine H1 Antagonists, Non-Sedating</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
